GPSno

GPSno characterizes the genetic and pharmacogenomic landscape of small nucleolar RNAs (snoRNAs) across 29 cancer types using The Cancer Genome Atlas (TCGA) data to link snoRNA expression with genetic variants, patient survival, GWAS risk loci, and drug response.

Key Features:

• Genetic variant–snoRNA association: Integrates genotype and snoRNA expression data to characterize effects of genetic variants on snoRNA expression across 29 TCGA cancer types.
• GWAS and survival linkage: Associates variant-linked changes in snoRNA expression with patient survival outcomes and overlaps with GWAS risk loci.
• Pharmacogenomic analysis: Examines associations between snoRNA expression and drug response in cancer patients to reveal pharmacogenomic relationships.

Scientific Applications:

• Tumorigenesis research: Elucidates roles of snoRNAs in cancer development to support biomarker discovery and therapeutic target prioritization.
• Clinical pharmacogenomics: Informs snoRNA-associated strategies for treatment stratification and development of targeted therapies based on drug response associations.

Methodology:

Analyzes genotype and snoRNA expression data from TCGA and computes correlations between genetic variants, snoRNA expression, patient survival, GWAS risk loci overlap, and drug response.